We investigated a possible association between markers of immune activation and disease activity in 52 patients with systemic lupus erythematosus (SLE). Serum concentrations of neopterin, beta- 2-microglobulin, 55 kD-type soluble tumor necrosis factor receptor, soluble interleukin-2 receptor and soluble CD8 were compared to the Index of European Consensus Lupus Activity Measurement (ECLAM). All markers of immune activation, except sCD8, significantly correlated with ECLAM. Stepwise multiple linear regression analysis revealed erythrocyte sedimentation rate and neopterin to correlate best with ECLAM (multiple correlation coefficient = 0.74, P < 0.001). The study shows that serum neopterin concentrations are a useful independent index for disease activity in SLE. The finding of enhanced concentrations of various parameters of immune activation in patients confirm a role of the T cell and macrophage activation in the pathogenesis of SLE.
Steinberg AD , Klinman DMPathogenesis of systemic lupus erythematosus . Rheum Dis Clin North Am1989; 14: 25-9.
2.
Linker-Israeli M., Deans RJ, Wallace DJ, Prehn J., Ozeri-Chen T., Klinenberg JRElevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol199 1; 147: 117-23.
3.
Linker-Israeli M.Cytokines abnormalities in human lupus. Clin Immunol Immunopathol1992; 63: 10-12.
4.
Linker-Israeli M., Wallace DJ, Jordan SC, Klinenberg JRDemonstration of IL-1, IL-6 and IFN gamma in SLE kidney biopsies. Arthritis Rheum1991 ; 34 (Suppl.): R20 (abstract).
5.
Hooks JJ, Jordan GW, Cupps T., Moutsopoulos HM, Fauci AS, Notkins ALMultiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum1982; 25: 396-400.
6.
Vitali C., Bencivelli W., Ienberg DADisease activity in systemic lupus erythematosus: report of the Consensus Study Group in the European Workshop for Rheumatology Research. II. Identification of the variables of disease activity and their use in the development of an activity score. Clin Exp Rheum1992; 10: 541-7.
Lim KL, Abdul-Wahab RA, Hughes J., Brown NS, Powell RJIs urine neopterin a good indicator of disease activity in patients with systemic lupus erythematosus? Comparison with ESR and C3 degradation products (C3dg) . Br J Rheum1992; 31: 56 (abstract).
9.
Lim K., Atta R., Hughes J., Brown NS, Powell RJIs urine neopterin a good indicator of disease activity in systemic lupus erythematosus (SLE)? Rev Esp Reumatol1993 ; 20 (Suppl. 1): 538 (abstract).
10.
Huber C., Batchelor JR, Fuchs D. et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med1984; 160: 310-16.
11.
Fuchs D., Hausen A., Reibnegger G., Werner ER, Dierich MP, Wachter H.Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today1988; 9: 150-5.
12.
Reibnegger G., Aichberger C., Fuchs D. et al. Post-transplant neopterin excretion in renal allograft recipients: a reliable diagnostic aid for acute rejection and a predictive marker of longterm graft survival. Transplantation1991; 52: 58-63.
13.
Reibnegger G., Egg D., Fuchs D. et al. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum1986; 29: 1063-70.
14.
Aderka D., Wysenbreek A., Engelmann H. et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum1993; 36: 1111-20.
15.
Cope AP, Aderka D., Doherty M. et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum1992; 35: 1160-9.
16.
Roux-Lombard P., Punzi L., Hasler F. et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum1993; 36: 485-9.
17.
Denz H., Orth B., Weiss G. et al. Serum soluble tumor necrosis factor receptor 55 is increased in patients with hematological neoplasias and is associated with immune activation and weight-loss. Eur J Cancer1993; 29A, 2232-5.
18.
Zangerle R. , Gallati H., Sarcletti M. et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr1994; 7: 75-80.
19.
Wolf RE, Brelstord WGSoluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum1988; 31: 729-35.
20.
Tomkinson BE , Brown MC, Ip SH, Carrabis S., Sullivan JLSoluble CD8 during T cell activation. J Immunol1989; 142: 2230-6.
Creswell P. , Springer T., Strominger JL, Turner MJ, Grey HM, Kubo RTImmunological identity of the small subunit of HLA-A and beta-2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci USA1974; 71: 2123-7.
23.
Fuchs D., Krämer A., Reibnegger G. et al. Neopterin and β2-microglobulin as prognostic indices in human immunodeficiency virus type I infection. Infection1991; 19 (Suppl. 2): S98-S102.
24.
Fuchs D., Hausen A., Reibnegger G. et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol1991; 46: 65-70.
25.
Samsonov M. , Reibnegger G., Nassonov E., Nassonova V., Wachter H., Fuchs D.Elevated serum neopterin levels in acute rheumatic fever. Pteridines1993; 4: 39-42.
26.
Fuchs D., Zangerle R., Artner-Dworzak E. et al. Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection. Eur J Haematol1993; 50: 90-4.
